Patents, Pipelines, and Pledges: Structuring Intangible Asset-Backed Lending for Pharmaceuticals and Life Sciences
Pharmaceuticals were among the first sectors to pioneer IP-backed financing through patent royalty securitisations. But the opportunity extends far beyond royalty streams. Drug patents, clinical data packages, regulatory approvals, and formulation know-how constitute a rich intangible asset base that most PE-backed pharma companies underexploit as collateral.
Read more →